Table 3: Demographic and clinical characteristics of RA patients and comparisons between subgroups.

VariablesLow baPWV group
( )
High baPWV group
( )
P

Age (years), mean ± SD 0.008
Female, n (%)60 (78.95)51 (82.26)0.626
Weight (kg), mean ± SD 0.325
Height (cm), mean ± SD 0.033
BMI (kg/m2), mean ± SD 0.389
SBP (mmHg), mean ± SD 0.084
DBP (mmHg), mean ± SD 0.215
Cholesterol (mmol/L), mean ± SD 0.035
Triglycerides (mmol/L), mean ± SD 0.004
HDL (mmol/L), mean ± SD 0.538
LDL (mmol/L), mean ± SD 0.006
Glucose (mmol/L), mean ± SD 0.434
Disease duration (months), mean (IQR)24 (8, 66)48 (12, 132)0.169
RF-IgG positive, n (%)46 (60.53)34 (54.84)0.501
RF-IgA positive, n (%)37 (48.68)28 (45.16)0.100
RF-IgM positive, n (%)56 (73.68)52 (83.87)0.149
Anti-CCP positive, n (%)55 (72.37)43 (69.35)0.698
ESR (mm/h), mean ± SD 0.172
CRP (mg/dL), mean (IQR)13.90 (5.34, 28.55)18.15 (6.24, 68.05)0.447
DAS28, mean ± SD 0.113
Currently using DMARDs, n (%)5 (6.58)4 (6.45)0.976
Currently using NSAIDs, n (%)38 (50.00)36 (58.06)0.345

Data are given as mean ± SD when normally distributed, as median (25–75%) when nonnormally distributed, or as number (and percentage). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: disease activity score for 28 joint indices; IQR: interquartile range; DMARDs: disease-modifying antirheumatic drugs; NSAIDs: nonsteroidal anti-inflammatory drugs.